Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 16, 2024, 12:25 a.m. and Nov. 23, 2024, 12:25 a.m. from: E-Discovery Services.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Document Date: Nov. 20, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: These agreements represent the most recent collaborations initiated under Flagship's strategic partnership with Pfizer Inc. (Pfizer) announced in July 2023 and will leverage Pfizer's deep expertise in early discovery and development for new targeted therapies. " These two new collaborations will separately leverage the pioneering bioplatform technologies of Ampersand and Montai to perform research, which may lead to future opportunities to develop new therapies in areas of critical unmet need ," said Paul Biondi, Flagship Pioneering General Partner and President of Pioneering Medicines. " With four Flagship-founded companies now actively working with our Pioneering Medicines team to advance research activities under our partnership with Pfizer, we are demonstrating how this Innovation Supply Chain Partnership could enable more rapid innovation by uniting Flagship's ecosystem of diverse bioplatforms with Pfizer's disease and therapeutic development expertise to bring about breakthroughs in drug development ." The agreements with Ampersand Biomedicines and Montai Therapeutics follow previously announced agreements with ProFound Therapeutics and Quotient Therapeutics, marking continued momentum for the partnership. Pioneering Medicines, Flagship's in house drug discovery and development unit, is responsible for leading Flagship's partnership with Pfizer, including driving the exploration process to rapidly surface potential drug discovery and research programs built on Flagship's diverse bioplatforms and modalities.
Document Source: https://www.prnewswire.com/news-releases/flagship-pioneering-announces-two-new-agreements-with-ampersand-biomedicines-and-montai-therapeutics-under-its-strategic-partnership-with-pfizer-302310557.html (archive.org page / archive.org listing)


Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Document Date: Nov. 20, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ - Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and non-small cell lung cancer (NSCLC) , two priority disease areas for Pfizer. These agreements represent the most recent collaborations initiated under Flagship's strategic partnership with Pfizer Inc. (Pfizer) announced in July 2023 and will leverage Pfizer's deep expertise in early discovery and development for new targeted therapies. " These two new collaborations will separately leverage the pioneering bioplatform technologies of Ampersand and Montai to perform research, which may lead to future opportunities to develop new therapies in areas of critical unmet need ," said Paul Biondi, Flagship Pioneering General Partner and President of Pioneering Medicines. " With four Flagship-founded companies now actively working with our Pioneering Medicines team to advance research activities under our partnership with Pfizer, we are demonstrating how this Innovation Supply Chain Partnership could enable more rapid innovation by uniting Flagship's ecosystem of diverse bioplatforms with Pfizer's disease and therapeutic development expertise to bring about breakthroughs in drug development ." The agreements with Ampersand Biomedicines and Montai Therapeutics follow previously announced agreements with ProFound Therapeutics and Quotient Therapeutics, marking continued momentum for the partnership.
Document Source: https://www.prnewswire.com/news-releases/flagship-pioneering-announces-two-new-agreements-with-ampersand-biomedicines-and-montai-therapeutics-under-its-strategic-partnership-with-pfizer-302310557.html (archive.org page / archive.org listing)


Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Document Date: Nov. 20, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: potential Non-Small Cell Lung Cancer-related target. Collaborations will leverage Pfizer's deep expertise in early discovery and development. for cardiometabolic and cancer treatments, two priority therapeutic areas for the. company. CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ - Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and non-small cell lung cancer (NSCLC) , two priority disease areas for Pfizer.
Document Source: https://www.prnewswire.com/news-releases/flagship-pioneering-announces-two-new-agreements-with-ampersand-biomedicines-and-montai-therapeutics-under-its-strategic-partnership-with-pfizer-302310557.html (archive.org page / archive.org listing)


Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS

Document Date: Nov. 20, 2024, 10 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Verge is eligible for additional downstream economics as the programs progress. " By providing us with scientifically compelling target predictions, which were supported by elegant validation experiments in human cell systems, the Verge team and CONVERGE® platform have delivered multiple promising therapeutic targets ," said Michael Hutton, Ph.D., Senior Vice President and CSO, Neurodegeneration and Genetic Medicine at Lilly. " We look forward to building upon their work with the aim of advancing ALS drug candidates to address the significant unmet patient needs in this fatal disease ." In 2021, Verge and Lilly entered into a 3-year collaboration to discover and validate novel therapeutic targets for ALS that would become the focus for subsequent drug discovery and development. Verge received up to $ 25 million in upfront, equity investment and potential near-term milestones, with a total deal value of $ 694 million plus potential downstream royalties.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984206/0/en/Verge-Genomics-Announces-Milestones-in-Collaboration-with-Lilly-to-Discover-and-Develop-Novel-Treatments-for-ALS.html (archive.org page / archive.org listing)


SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

Document Date: Nov. 19, 2024, midnight / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: This marks the first collaborative research agreement in which both sides will aim to discover radiopharmaceutical compounds and investigate novel oncological treatments, using actinium-225 (225Ac) , an alpha-particle emitting radioisotope that selectively kills cancer cells. The research for radiopharmaceutical therapy (RPT) focuses on this application that has been gaining attention for its high potential in nuclear medicine. SK Biopharmaceuticals has already initiated its 225Ac - based research as it secured a supply of the radioisotope from TerraPower Isotopes, a subsidiary of TerraPower, a nuclear innovation company whose investors include SK Biopharmaceuticals' parent SK Inc. and Bill Gates. SK Biopharmaceuticals and KIRAMS will seek to submit an Investigational New Drug application by 2027, as they leverage each other's resources to optimize their drug discovery efforts. SK Biopharmaceuticals said it could significantly reduce the time and cost of new drug development, with KIRAMS' researchers, facilities and equipment using the radioisotope, enabling the company to further accelerate in securing and expanding its RPT pipeline and capability.
Document Source: https://www.prnewswire.com/news-releases/sk-biopharmaceuticals-seals-1st-actinium-225-based-collaborative-research-agreement-with-korea-institute-of-radiological-and-medical-sciences-as-steps-toward-becoming-global-radiopharmaceutical-therapy-player-302308104.html (archive.org page / archive.org listing)


SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

Document Date: Nov. 19, 2024, midnight / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: SK Biopharmaceuticals and KIRAMS will seek to submit an Investigational New Drug application by 2027, as they leverage each other's resources to optimize their drug discovery efforts. SK Biopharmaceuticals said it could significantly reduce the time and cost of new drug development, with KIRAMS' researchers, facilities and equipment using the radioisotope, enabling the company to further accelerate in securing and expanding its RPT pipeline and capability. The agreement is in line with SK Biopharmaceuticals' so-called "RPT Roadmap" recently introduced to become a global leading RPT player by 2027, as the company will fortify its RPT business by discovering new drug compounds, extending supply and production capacities, and developing a tech platform, via strengthened internal assets and strategic partnerships. In addition to the 225Ac supply agreement aligned with its roadmap, the company has in-licensed SKL35501 (FL-091) radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) solid tumors. Jinkyung Lee, President of KIRAMS, stated, "Through this joint research agreement, we aim to take a leading role in developing innovative radiopharmaceutical therapeutics, in alignment with the Ministry of Science and ICT's strategic initiative to drive advancements in Radiation Biology.
Document Source: https://www.prnewswire.com/news-releases/sk-biopharmaceuticals-seals-1st-actinium-225-based-collaborative-research-agreement-with-korea-institute-of-radiological-and-medical-sciences-as-steps-toward-becoming-global-radiopharmaceutical-therapy-player-302308104.html (archive.org page / archive.org listing)


SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

Document Date: Nov. 19, 2024, midnight / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Republic of Korea
Partnership: Document Extract: SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha - particle emitting radioisotope, actinium - 225, for potential cancer treatments. - - The two sides aim to submit an Inves tigational New Drug application by 2027, in line with SK Biopharmaceuticals' roadmap to strengthen its radiopharmaceutical therapy business. SK Biopharmaceuticals further accelerates the expansion of its radiopharmaceutical therapy pipeline and capability, via strengthened internal resources and partnerships. SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ - SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS) , Korea's premier research institution dedicated to the study and advancement of radiological and medical sciences, to collaborate on discovering and developing preclinical radiopharmaceutical drug candidates. This marks the first collaborative research agreement in which both sides will aim to discover radiopharmaceutical compounds and investigate novel oncological treatments, using actinium-225 (225Ac) , an alpha-particle emitting radioisotope that selectively kills cancer cells.
Document Source: https://www.prnewswire.com/news-releases/sk-biopharmaceuticals-seals-1st-actinium-225-based-collaborative-research-agreement-with-korea-institute-of-radiological-and-medical-sciences-as-steps-toward-becoming-global-radiopharmaceutical-therapy-player-302308104.html (archive.org page / archive.org listing)


Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

Document Date: Nov. 19, 2024, 4:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies. Orion Corporation and Alligator Bioscience AB have agreed on the conversion of the previously granted royalty-bearing license to Orion Corporation to two bispecific antibodies that the companies have been successfully developing in collaboration using Alligator's RUBY® bispecific format to a perpetual, fully paid, royalty-free license. Orion will continue to develop these antibodies, which are currently in late-stage pre-clinical development, without any obligation to pay any milestone payments or royalties to Alligator. In connection with the amendment of the agreement, Orion pays Alligator a one-time payment of EUR 3.5 million. Contact person:
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983850/0/en/Orion-and-Alligator-Bioscience-amend-their-agreement-concerning-two-bispecific-antibodies.html (archive.org page / archive.org listing)


Esperanto Technologies and NEC Cooperate on Initiative to Advance Next Generation RISC-V Chips and Software Solutions for HPC

Document Date: Nov. 18, 2024, 1 p.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Esperanto Technologies™, a leading developer of RISC-V chips and software for high-performance computing (HPC) and artificial intelligence (AI) , today announced that they are cooperating with NEC Corporation on the roadmap for next-generation chips and software for HPC computing. The goal of the cooperation is to facilitate the further development of hardware and software solutions to enable the next generation of supercomputers based on the RISC-V instruction set. The cooperation is expected to leverage NEC's deep experience and expertise in HPC supercomputer design and development of HPC software stacks along with Esperanto's technology and expertise in high-performance energy-efficient multiprocessor chips based on the RISC-V instruction set. NEC Corporation has a long and influential history in supercomputing and HPC, providing systems that meets customer needs by integrating its CPU, GPU and vector solutions. What makes the company unique is their vector processor, which has been developed over decades.
Document Source: https://www.businesswire.com/news/home/20241118266658/en/Esperanto-Technologies-and-NEC-Cooperate-on-Initiative-to-Advance-Next-Generation-RISC-V-Chips-and-Software-Solutions-for-HPC (archive.org page / archive.org listing)


Aclaris Therapeutics Announces $80 Million Private Placement

Document Date: Nov. 18, 2024, 1:10 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: United States
Investor: Target: Document Extract: WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the "Company" or "Aclaris") , a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $ 2.25 per share, for gross proceeds of approximately $ 80.0 million.
Document Source: https://www.globenewswire.com/news-release/2024/11/18/2982760/37216/en/Aclaris-Therapeutics-Announces-80-Million-Private-Placement.html (archive.org page / archive.org listing)


Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Document Date: Nov. 18, 2024, 1:10 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity / Region: Wayne
Partnership: Document Extract: WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ: ACRS) , a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R. " This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with both small and large molecule drugs ," said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris. " Despite recent advances with anti-TSLP and anti-IL4R therapies, there remains substantial unmet need for more effective and convenient treatment options. BSI-045B's compelling Phase 2a proof-of-concept data in atopic dermatitis, together with BSI-502's dual-targeting approach, complement our existing ITK inhibitor portfolio, resulting in a pipeline of differentiated assets that targets multiple high-value indications. In addition, the proceeds from the private placement financing announced this morning bolsters our balance sheet and provides us with enhanced financial flexibility to support our strategic growth while maintaining our cash runway into 2028 ."
Document Source: https://www.globenewswire.com/news-release/2024/11/18/2982759/37216/en/Aclaris-Therapeutics-Announces-Exclusive-Global-License-Agreement-with-Biosion-Inc-adding-Potential-Best-in-Class-Biologics-Assets-to-Pipeline.html (archive.org page / archive.org listing)


Consilio Appoints Emron Pratt as Chief Strategy and Transformation Officer

Document Date: Nov. 19, 2024, 2:01 p.m. / Source: Business Wire
Activity Class: RoleActivity / Type: Starting
Role: Person: Organization: Document Extract: Consilio, the global leader in legal technology solutions and enterprise legal services, today announced the appointment of Emron Pratt as the company's first Chief Strategy and Transformation Officer.
Document Source: https://www.businesswire.com/news/home/20241119380874/en/Consilio-Appoints-Emron-Pratt-as-Chief-Strategy-and-Transformation-Officer (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? No (Turn On)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.